Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27684303 | 0.95 | — | — | |
| SCHEMBL5671706 | 0.77 | TP53 (0.36) | — | |
| SCHEMBL216434 | 0.75 | TP53 (0.35) | — | |
| SCHEMBL2800618 | 0.75 | TP53 (0.35) | — | |
| SCHEMBL8871105 | 0.73 | TSHR (0.30) | — | |
| SCHEMBL27465287 | 0.73 | TSHR (0.30) | — | |
| SCHEMBL3362691 | 0.71 | HTT (0.30) | — | |
| SCHEMBL6377049 | 0.71 | HTT (0.30) | — | |
| SCHEMBL2254132 | 0.70 | TSHR (0.41) | — | |
| SCHEMBL10932775 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708799-B | Cured product of organic phosphine modified unsaturated polyester and polyhalide and preparation method thereof | 浙江工业大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119708799-A | Cured product of organic phosphine modified unsaturated polyester and polyhalide and preparation method thereof | 浙江工业大学 | 2025-03-28 | — | — | CN | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-116687912-A | Use of gomisin N and derivatives thereof in the treatment of liver injury related diseases | 上海交通大学医学院附属第九人民医院 | 2023-09-05 | — | — | CN | claimed |
| CN-115887390-A | Diisopropylamine dichloroacetate sodium gluconate freeze-dried composition for injection and application | 山东北大高科华泰制药有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115737633-A | Traditional Chinese medicine active monomer with liver protection effect and application thereof | 上海交通大学医学院附属第九人民医院 | 2023-03-07 | — | — | CN | claimed |
| CN-114892357-A | Antibacterial anti-aging textile material, preparation method and device | 江门职业技术学院 | 2022-08-12 | — | — | CN | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| CN-109806263-A | A kind of pharmaceutical composition and its preparation method and application | 中国药科大学 | 2019-05-28 | — | — | CN | claimed |
| CN-109419692-A | A kind of ecchymose removing dampness elimination gas shin moisturizer | 汕头市精湛财务咨询有限公司 | 2019-03-05 | — | — | CN | claimed |
| CN-1443575-A | Medicine for curing metabolic syndrome | LIAONING YILIAN NEW MEDICINE I (CN) | 2003-09-24 | — | — | CN | claimed |
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002072039-A2 | TOPICAL PREPARATIONS AND FOOD PREPARATIONS COMPRISING A PYRIDOXINE-ALPHA-D-GLUCOSE | PENTAPHARM LTD (CH) | 2002-09-19 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162824-A1 | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor | PTGS1, PTGIS, TNNT2 | LMNA 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.